ExaGrid Wins 3 Awards at 12th Annual SDC Awards
30.11.2021 16:00:00 EET | Business Wire | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with three awards at the 12th annual SDC Awards ceremony, Angel Business Communications’ premier IT awards – the Storage, Digitalisation + Cloud Awards, held in London on November 24, 2021. These new award wins add to ExaGrid’s previous six wins this past fall, totaling nine industry awards in 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005225/en/
ExaGrid wins 3 awards at the 12th annual SDC Awards, held in London on November 24, 2021. (Photo: Business Wire)
ExaGrid’s Reseller Partner Program has been voted “Vendor Channel Program of the Year” for a second year in a row. In 2021, ExaGrid rolled out an optional Solutions Architects certification at no charge to become an ExaGrid Certified Engineer. ExaGrid works with resellers and distributors worldwide. The ExaGrid programs are designed to be easy for partners, with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that ‘just works’ and provides its customers with stellar customer support from an assigned level 2 engineer, ensuring that partners’ customers are well taken care of.
ExaGrid Tiered Backup Storage has been voted “Storage Hardware Innovation of the Year” for a second year in a row. In January of 2021, ExaGrid announced a new line of appliances, including the EX84, its largest appliance to date. The largest configuration, made up of 32 EX84 appliances in a single scale-out system, allows for a full backup of up to 2.7PB with a single deduplicated repository, which is 50% larger than any other system on the market. The net is that ExaGrid offers fast backups, fast restores, a fixed-length backup window as data grows due to its scale-out architecture, ransomware recovery of encrypted primary data, and a system that scales to 50% greater capacity than any other solution in the industry.
ExaGrid Tiered Backup Storage has been voted “Storage Company of the Year” for a second year in a row. In 2021, ExaGrid expanded its product line with greater scalability up to 2.7PB full backup to a single system and well as reduced data center footprint by 30%. ExaGrid has advanced it tools and calculators to further assist customer in calculating the true cost of backup storage up front and over time. These tools show customers what their costs of backup storage will be inclusive of backup retention, yearly data growth, and storage for second site disaster recovery. ExaGrid has had back-to-back record quarters in 2021, and has expanded its customer base to over 3,100 customers in 50 countries. ExaGrid is the only company that is completely dedicated to backup storage, with a goal to solve the issues commonly experienced with backup solutions while providing the best value to its customers.
“We are so honored to win these three awards for a second year in a row, as they each speak to our company’s strengths – an innovative backup storage architecture, a customer-focused approach with high-quality support, and a strong channel program,” said Bill Andrews, President and CEO of ExaGrid. “Congratulations to all of this year’s winners! These awards are decided on by public vote so it means so much to us, and we are so thankful to everyone who voted, and to all of our partners, customers, and staff for their support.”
ExaGrid continues to gain recognition for its Tiered Backup Storage appliances, winning 9 awards in the fall of 2021, including:
- Storage Awards “The Storries XVIII” - Enterprise Backup Hardware Vendor of the Year
- Storage Awards “The Storries XVIII” - Immutable Storage Company of the Year
- Network Computing Awards - Company of the Year
- Network Computing Awards - Bench Tested Product of the Year
- Network Computing Awards - Storage Product of the Year
- Network Computing Awards - The Return on Investment award
- SDC Awards - Vendor Channel Program of the Year
- SDC Awards - Storage Hardware Innovation of the Year
- SDC Awards - Storage Company of the Year
ExaGrid Tiered Backup Storage – Built for Backup
ExaGrid provides Tiered Backup Storage with a front-end disk-cache Landing Zone, the Performance Tier, which writes data directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. The long-term retention data is tiered to a deduplicated data repository, the Retention Tier, to reduce the amount of retention storage and resulting cost. This two-tiered approach provides the fastest backup and restore performance with lowest cost storage efficiency.
In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system, which eliminates product obsolescence while protecting IT investments up front and over time.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005225/en/
Contact information
Media:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom